Literature DB >> 11422116

Urate and arteriosclerosis in primary hyperparathyroidism.

J Westerdahl1, S Valdemarsson, P Lindblom, A Bergenfelz.   

Abstract

OBJECTIVE: An increased mortality due to cardiovascular disease has been reported in patients with primary hyperparathyroidism (pHPT). An association between urate and cardiovascular disease has been suggested. Metabolic abnormalities in pHPT may include urate. We therefore evaluated the metabolic arteriosclerotic risk profile in pHPT with special focus on the role of urate.
DESIGN: Retrospective analysis of data before and 1 year after surgery for pHPT. PATIENTS: 130 consecutive patients, over the age of 44 years, who underwent surgery for pHPT. MEASUREMENTS: Biochemical variables known to reflect risk of arteriosclerotic disease (AD) and renal function tests including measurement of glomerular filtration rate (GFR) were investigated before and 1 year after surgery.
RESULTS: pHPT patients with AD (n = 40) were older and had higher serum levels of urate and triglyceride, and more impaired renal function in comparison with patients without AD. PTH and calcium values did not differ. Multiple logistic regression analysis indicated that urate was an independent risk factor for AD in pHPT (P < 0.01). Three variables were shown to be positively associated with urate; male gender (P < 0.01), fasting blood glucose (P < 0.05) and serum level of triglyceride (P < 0.05).
CONCLUSIONS: Urate was found to be an independent risk factor for arteriosclerotic disease in primary hyperparathyroidism. Serum level of urate could (in addition to gender) be associated with a metabolic disorder comprising increased glucose and triglyceride levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422116     DOI: 10.1046/j.1365-2265.2001.01265.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  The role of uric acid in mineral bone disorders in chronic kidney disease.

Authors:  Baris Afsar; Alan A Sag; Cinar Oztosun; Masanari Kuwabara; Mario Cozzolino; Adrian Covic; Mehmet Kanbay
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

2.  Cardiovascular risk factors in primary hyperparathyroidism.

Authors:  R Luboshitzky; Y Chertok-Schaham; I Lavi; A Ishay
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

Review 3.  Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions.

Authors:  R E Simoni; L N L Ferreira Gomes; F B Scalco; C P H Oliveira; F R Aquino Neto; M L Costa de Oliveira
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

4.  Arterial Hypertension, Metabolic Syndrome and Subclinical Cardiovascular Organ Damage in Patients with Asymptomatic Primary Hyperparathyroidism before and after Parathyroidectomy: Preliminary Results.

Authors:  Petramala Luigi; Formicuccia Maria Chiara; Zinnamosca Laura; Marinelli Cristiano; Cilenti Giuseppina; Colangelo Luciano; Panzironi Giuseppe; Cerci Sabrina; Sciomer Susanna; Ciardi Antonio; Cavallaro Giuseppe; De Toma Giorgio; Letizia Claudio
Journal:  Int J Endocrinol       Date:  2012-06-07       Impact factor: 3.257

5.  Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.

Authors:  Emily S Andrews; Loni Perrenoud; Kristen L Nowak; Zhiying You; Andreas Pasch; Michel Chonchol; Jessica Kendrick; Diana Jalal
Journal:  PLoS One       Date:  2018-10-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.